Project name
Real-world data collection on the diagnosis, disease course and outcomes for patients suffering from PROgressive Fibrosing Interstitial Lung Disease (RPROFILD)
Project abbreviation
RPROFILD
Project code
HDBP0244
Primary organization that oversees implementation of project
- Boehringer Ingelheim Comm.
Partner organization participating in project
- Not applicable
Organization that commissioned this project
- National Institute for Health and Disability Insurance (RIZIV-INAMI)
Organization providing monetary or material support
- Boehringer Ingelheim Comm.
Brief project description
Ofev® is reimbursed in Belgium in two indications: Idiopathic Pulmonary Fibrosis (IPF, paragraph 7780000) and non-IPF progressive fibrosing interstitial lung disease (non-IPF PF-ILD, paragraph 11530000). Progressive fibrosing interstitial lung disease (PF-ILD) is the umbrella terminology used for IPF + non-IPF PF-ILD. PF-ILDs are characterized by a self-sustaining progressive fibrosis of the lung, worsening respiratory symptoms, declining lung function, worsening quality of life, and early death in absence of active treatment. Ofev® is an efficacious and safe antifibrotic treatment that delays the lung function decline (measured as forced vital capacity (FVC) decline) of affected patients.
Regulatory framework of this project
Consult the regulatory framework information published on the fair.healthdata.be pages.